WO1995034679A3 - Defects in drug metabolism - Google Patents

Defects in drug metabolism Download PDF

Info

Publication number
WO1995034679A3
WO1995034679A3 PCT/US1995/007605 US9507605W WO9534679A3 WO 1995034679 A3 WO1995034679 A3 WO 1995034679A3 US 9507605 W US9507605 W US 9507605W WO 9534679 A3 WO9534679 A3 WO 9534679A3
Authority
WO
WIPO (PCT)
Prior art keywords
drug metabolism
defects
cyp2a6
mutations
absence
Prior art date
Application number
PCT/US1995/007605
Other languages
French (fr)
Other versions
WO1995034679A2 (en
Inventor
Frank J Gonzalez
Jeffrey R Idle
Original Assignee
Us Health
Frank J Gonzalez
Jeffrey R Idle
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GB9412054A external-priority patent/GB9412054D0/en
Priority claimed from GBGB9502728.0A external-priority patent/GB9502728D0/en
Priority claimed from GBGB9507640.2A external-priority patent/GB9507640D0/en
Application filed by Us Health, Frank J Gonzalez, Jeffrey R Idle filed Critical Us Health
Priority to AU28602/95A priority Critical patent/AU2860295A/en
Priority to US08/750,703 priority patent/US5891633A/en
Priority to GB9626479A priority patent/GB2303853B/en
Publication of WO1995034679A2 publication Critical patent/WO1995034679A2/en
Publication of WO1995034679A3 publication Critical patent/WO1995034679A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/0004—Oxidoreductases (1.)
    • C12N9/0071—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14)
    • C12N9/0077—Oxidoreductases (1.) acting on paired donors with incorporation of molecular oxygen (1.14) with a reduced iron-sulfur protein as one donor (1.14.15)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/156—Polymorphic or mutational markers

Abstract

The invention relates to genetic material, and specifically portions of DNA, for identifying the presence or absence of a mutation in the drug metabolism gene CYP2C9 and CYP2A6. Further, the invention comprises a method for determining such mutations and a kit incorporating the genetic material of the invention for performing the said methods so as to determine the presence or absence of mutations in the drug metabolizing gene CYP2C9 and CYP2A6.
PCT/US1995/007605 1994-06-16 1995-06-16 Defects in drug metabolism WO1995034679A2 (en)

Priority Applications (3)

Application Number Priority Date Filing Date Title
AU28602/95A AU2860295A (en) 1994-06-16 1995-06-16 Defects in drug metabolism
US08/750,703 US5891633A (en) 1994-06-16 1995-06-16 Defects in drug metabolism
GB9626479A GB2303853B (en) 1994-06-16 1995-06-16 Variant alleles in cytochrome P450 expressing enzymes involved in metabolic processes

Applications Claiming Priority (6)

Application Number Priority Date Filing Date Title
GB9412054.0 1994-06-16
GB9412054A GB9412054D0 (en) 1994-06-16 1994-06-16 Defects in drug metabolism
GBGB9502728.0A GB9502728D0 (en) 1994-06-16 1995-02-13 Defects in drug metabolism
GB9502728.0 1995-02-13
GBGB9507640.2A GB9507640D0 (en) 1995-04-12 1995-04-12 Defects in drug metabolism
GB9507640.2 1995-04-12

Publications (2)

Publication Number Publication Date
WO1995034679A2 WO1995034679A2 (en) 1995-12-21
WO1995034679A3 true WO1995034679A3 (en) 1996-03-21

Family

ID=27267237

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/007605 WO1995034679A2 (en) 1994-06-16 1995-06-16 Defects in drug metabolism

Country Status (3)

Country Link
AU (1) AU2860295A (en)
GB (1) GB2303853B (en)
WO (1) WO1995034679A2 (en)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113215121B (en) * 2021-06-07 2021-12-17 云南师范大学 Method for efficiently and heterogeneously synthesizing mogroside V precursor

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9422205D0 (en) * 1994-11-03 1994-12-21 British Gas Plc Enzyme mutant and method
WO1997016553A1 (en) * 1995-11-01 1997-05-09 Bg Plc MUTANT MONO-OXYGENASE CYTOCHROME P450cam
US6117661A (en) * 1995-11-01 2000-09-12 Bg Plc Mutant mono-oxygenase cytochrome P450cam
NZ334205A (en) * 1996-07-17 2001-04-27 Nicogen Inc Method for regulating nicotine metabolism through inhibition of CYP2A6 and CYP2B6 liver enzymes
CA2312851A1 (en) * 1997-12-01 1999-06-10 Nicogen, Inc. Therapeutic and diagnostic methods dependent on cyp2a enzymes
US6908631B1 (en) 1997-12-01 2005-06-21 Nicogen, Inc. Therapeutic and diagnostic methods dependent on CYP2A enzymes
WO2000009682A1 (en) * 1998-08-12 2000-02-24 Maxygen, Inc. Dna shuffling of monooxygenase genes for production of industrial chemicals
WO2000012757A1 (en) * 1998-08-28 2000-03-09 Sangtec Molecular Diagnostics Ab A method for measuring a patient's ability to metabolise certain drugs
WO2000043003A1 (en) * 1999-01-21 2000-07-27 Darwin Discovery Limited The therapeutic use of r-warfarin as anticoagulant
AU4144600A (en) 1999-04-28 2000-11-17 Sumitomo Pharmaceuticals Company, Limited Cyp2a6 gene judgment methods
US6492115B1 (en) 2000-06-02 2002-12-10 Dna Sciences Laboratories, Inc. Genetic typing of the human cytochrome P450 2A6 gene and related materials and methods
AU2003280262A1 (en) * 2002-06-28 2004-01-19 Xanthus Life Sciences, Inc. Individualization of therapy with anticoagulants
ES2453895T3 (en) 2003-09-23 2014-04-08 University Of North Carolina At Chapel Hill Cells expressing vitamin K epoxide reductase and use thereof
US7445896B2 (en) 2004-10-18 2008-11-04 University Of Washington Methods and compositions for detecting VKORC1 single nucleotide polymorphisms
WO2006044686A2 (en) * 2004-10-18 2006-04-27 University Of Washington Methods and compositions for predicting drug responses
CA2601574C (en) 2005-03-15 2014-12-02 University Of North Carolina At Chapel Hill Methods and compositions for producing active vitamin k-dependent proteins
EP2655607A4 (en) 2010-12-21 2014-05-14 Univ North Carolina Methods and compositions for producing active vitamin k-dependent proteins

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001990A1 (en) * 1989-07-26 1991-02-21 City Of Hope Chimeric anti-cea antibody
WO1994001548A2 (en) * 1992-07-13 1994-01-20 Medical Research Council Human nucleic acid fragments, isolated from brain adrenal tissue, placenta or bone narrow

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1991001990A1 (en) * 1989-07-26 1991-02-21 City Of Hope Chimeric anti-cea antibody
WO1994001548A2 (en) * 1992-07-13 1994-01-20 Medical Research Council Human nucleic acid fragments, isolated from brain adrenal tissue, placenta or bone narrow

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
FERNANDEZ-SALUERO, P. ET AL: "A genetic polymorphism in coumarin 7-hydroyxlation", AMERICAN JOURNAL OF HUMAN GENETICS, vol. 57, pages 651 - 660 *
TIANO, H. ET AL: "retroviral mediated expression of human cytochrome P450 2A6 in CH3/10T1/2 cells confers transformability by NNK.", CARCINOGENESIS, vol. 14, no. 7, pages 1421 - 1427 *
YAMANO S ET AL: "The CYPA3 gene product catalyses coumarin hydroxylation in human liver microsomes", BIOCHEMISTRY, vol. 29, pages 1322 - 29 *

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN113215121B (en) * 2021-06-07 2021-12-17 云南师范大学 Method for efficiently and heterogeneously synthesizing mogroside V precursor

Also Published As

Publication number Publication date
GB9626479D0 (en) 1997-02-05
WO1995034679A2 (en) 1995-12-21
GB2303853B (en) 1998-12-23
GB2303853A (en) 1997-03-05
AU2860295A (en) 1996-01-05

Similar Documents

Publication Publication Date Title
WO1995034679A3 (en) Defects in drug metabolism
IL91501A0 (en) Binding protein
WO1998030883A3 (en) Analysis of genetic polymorphisms and gene copy number
WO2001029257A3 (en) Methods of genetic cluster analysis
WO2000001823A3 (en) Flt3-l mutants and methods of use
WO1999013077A3 (en) Inducible methods for repressing gene function
ATE327335T1 (en) METHOD FOR ALTERING THE SUBSTRATE SPECIFICITY OF ENZYMES
AU6252796A (en) Nucleic acid repair enzyme methods for point mutation detect ion and in vitro mutagenesis
AU3822199A (en) Basb013 dna and proteins from neisseria meningitidis
AU2687397A (en) Method and reagents for testing for mutations in the brca1 gene
van Meijer et al. Selective Screening of a Large Phage Display Library of Plasminogen Activator Inhibitor 1 Mutants to Localize Interaction Sites with Either Thrombin or the Variable Region 1 of Tissue-type Plasminogen Activator (∗)
AU2215897A (en) Methods and compositions for detecting dihydropyrimidine dehydrogenase splicing mutations
EP0857780A4 (en) Novel proteins remarkably expressed in liver cancer, genes encoding the same, antibodies against the same, and method for detecting the expression of the same
ATE257515T1 (en) GENES FOR BUTYROBETAIN/CROTONOBETAIN-L-CARNITINE METABOLISM AND THEIR USE FOR MICROBIOLOGICAL PRODUCTION OF L-CARNITINE
WO1995017522A3 (en) Identification of simple tandem repeats
WO1997035878A3 (en) The porcine heart fatty acid-binding protein encoding gene and methods to identify polymorphisms associated with body weight
WO2000031253A3 (en) Mutation of the parkin gene, compositions, methods and uses
WO2001007649A3 (en) Method for detecting microorganisms
EP1016717A4 (en) Novel protein remarkably expressed in hepatic cancer, gene encoding the same, antibody thereto, and method for detecting the expression thereof
AU2002245350A1 (en) Methods for determining the genetic affinity of microorganisms and viruses
AU2905497A (en) Methods for identifying a mutation in a gene of interest
AU2001273842A1 (en) Method for identifying and isolating genome fragments with linkage disequilibrium
WO2001023616A3 (en) Method of identifying pathogenic cryptococci
Seeberg et al. Properties of the uvrABC endonuclease from E. coli.
WO2001006001A3 (en) Dna for detecting changes in chromosome 8

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AM AT AU BB BG BR BY CA CH CN CZ DE DK EE ES FI GB GE HU IS JP KE KG KP KR KZ LK LR LT LU LV MD MG MN MW MX NO NZ PL PT RO RU SD SE SG SI SK TJ TT UA UG US UZ VN

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN ML MR NE SN TD TG

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWE Wipo information: entry into national phase

Ref document number: 08750703

Country of ref document: US

122 Ep: pct application non-entry in european phase
NENP Non-entry into the national phase

Ref country code: CA